February 25, 2008
Prospector
Profile
225-04
 
Interpharm Holdings, Inc. NAICS 325412
75 Adams Avenue Hauppauge, NY 11788 Description Pharmaceuticals Mfg.
(631) 952-0214 Employees 670
http://www.interpharminc.com Revenue (mil) 75.5900
  Income (mil) -14.0600
  Assets (mil) 74.3700
  Liability (mil) 62.9600
  (for the year ended )
 
Category: Loss/Deficit
 
Event: Interpharm Holdings Inc.'s consolidated balance sheet at December 31, 2007, showed $64.3 million in total assets, $53.1 million in total liabilities, and $16.5 million in redeemable convertible preferred stock, resulting in a $5.3 million total stockholders' deficit. At December 31, 2007, the company's consolidated balance sheet also showed strained liquidity with $27.4 million in total current assets available to pay $44.0 million in total current liabilities. The company reported a net loss of $10.9 million on net sales of $16.2 million for the second quarter ended December 31, 2007, compared with a net loss of $4.1 million on net sales of $17.5 million in the same period ended December 31, 2006.
 
Intellectual Property: Interpharm owns the registered trademark REPRAXIN. [SEC Filing 10-K 11-15-07]
 
Description: Interpharm Holdings, through its subsidiary, Interpharm, Inc., engages in the development, manufacture, and marketing of generic prescription strength and over-the-counter pharmaceuticals in the United States.
 
Officers: Dr. Maganlal K. Sutaria (Chair); Cameron Reid (CEO); Peter Giallorenzo (EVP, COO & CFO); Kenneth Cappel (EVP & Gen. Counsel); Raj Sutaria (EVP); Jeffrey Weiss (EVP); Jonathan Berlent (SVP); David Reback (Dir.); Stewart Benjamin (Dir.); Kennith Johnson (Dir.); Richard J. Miller (Dir.); Joan P. Neuscheler (Dir.)
 
Auditor: Marcum & Kliegman LLP
 
Securities: Common stock symbol IPA; AMEX;
 
 
 
return to main page